Treating ALK-positive lung cancer—early successes and future challenges
作者： D. Ross Camidge , Robert C. Doebele
DOI: 10.1038/NRCLINONC.2012.43
关键词: Drug resistance 、 Oncology 、 Crizotinib 、 Internal medicine 、 Anaplastic lymphoma kinase 、 Drug 、 Lung cancer 、 Immunology 、 Medicine 、 Adverse effect 、 Disease 、 ALK-Positive
摘要: … ALK to act as an oncogene in many different cancers, especially non-small-cell lung cancer (NSCLC) that has heightened interest in ALK … licensed ALK inhibitor for ALK-positive (ALK+) …
nature.com
sci-hub.se 参考文章(98)
J W Vardiman, M M Le Beau, M A Bitter, R A Larson, C M Rubin, E D Ellis, L A Doane, W A Franklin, M E Kadin, The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia. ,vol. 3, pp. 866- 870 ,(1989)
Janakiraman Subramanian, Ramaswamy Govindan, Lung Cancer in ‘Never-Smokers’: A Unique Entity Oncology. ,vol. 24, pp. 29- 35 ,(2010)
Andrew J. Weickhardt, Micol S. Rothman, Smita Salian-Mehta, Katja Kiseljak-Vassiliades, Ana B. Oton, Robert C. Doebele, Margaret E. Wierman, D. Ross Camidge, Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. ,vol. 118, pp. 5302- 5309 ,(2012) , 10.1002/CNCR.27450
Emiko Sugawara, Yuki Togashi, Naoto Kuroda, Seiji Sakata, Satoko Hatano, Reimi Asaka, Takeshi Yuasa, Junji Yonese, Masanobu Kitagawa, Hiroyuki Mano, Yuichi Ishikawa, Kengo Takeuchi, Identification of Anaplastic Lymphoma Kinase Fusions in Renal Cancer Large-Scale Immunohistochemical Screening by the Intercalated Antibody-Enhanced Polymer Method Cancer. ,vol. 118, pp. 4427- 4436 ,(2012) , 10.1002/CNCR.27391
Christin A. Knowlton, Luther W. Brady, Rebecca C. Heintzelman, Radiotherapy in the treatment of gastrointestinal stromal tumor Rare Tumors. ,vol. 3, pp. 35- ,(2011) , 10.4081/RT.2011.E35
Robert C. Doebele, Xian Lu, Christopher Sumey, DeLee A. Maxson, Andrew J. Weickhardt, Ana B. Oton, Paul A. Bunn, Anna E. Barón, Wilbur A. Franklin, Dara L. Aisner, Marileila Varella-Garcia, D. Ross Camidge, Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer Cancer. ,vol. 118, pp. 4502- 4511 ,(2012) , 10.1002/CNCR.27409
Sen Zhang, Frank Wang, Jeffrey Keats, Xiaotian Zhu, Yaoyu Ning, Scott D. Wardwell, Lauren Moran, Qurish K. Mohemmad, Rana Anjum, Yihan Wang, Narayana I. Narasimhan, David Dalgarno, William C. Shakespeare, Juan J. Miret, Tim Clackson, Victor M. Rivera, Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chemical Biology & Drug Design. ,vol. 78, pp. 999- 1005 ,(2011) , 10.1111/J.1747-0285.2011.01239.X
June Koo Lee, Heae Surng Park, Dong‐Wan Kim, Kimary Kulig, Tae Min Kim, Se‐Hoon Lee, Yoon‐Kyung Jeon, Doo Hyun Chung, Dae Seog Heo, Woo‐Ho Kim, Yung‐Jue Bang, None, Comparative analyses of overall survival in patients with anaplastic lymphoma kinase‐positive and matched wild‐type advanced nonsmall cell lung cancer Cancer. ,vol. 118, pp. 3579- 3586 ,(2012) , 10.1002/CNCR.26668
M. G. Kris, B. E. Johnson, D. J. Kwiatkowski, A. J. Iafrate, I. I. Wistuba, S. L. Aronson, J. A. Engelman, Y. Shyr, F. R. Khuri, C. M. Rudin, E. B. Garon, W. Pao, J. H. Schiller, E. B. Haura, K. Shirai, G. Giaccone, L. D. Berry, K. Kugler, J. D. Minna, P. A. Bunn, Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). Journal of Clinical Oncology. ,vol. 29, ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.CRA7506
Nikolas von Bubnoff, Folker Schneller, Christian Peschel, Justus Duyster, BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study The Lancet. ,vol. 359, pp. 487- 491 ,(2002) , 10.1016/S0140-6736(02)07679-1